Character Biosciences Raises $93M in Series B Round

Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, raises $93 million in Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration.

• Funding was co-led by new investors aMoon and Luma Group, with additional participation from Bausch + Lomb and Jefferson Life Sciences, alongside existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures
• Series B funding will support Phase 1 and Phase 2 proof-of-concept studies for CTX203 and CTX114, as well as the expansion of Character Bio’s ...